Categorical variables were compared using either the chi-square or Fisher's exact test (2) and continuous variables were compared using either the Wilcoxon rank sum test or Students t-test as deemed suitable
Furthermore, pemvidutide is currently undergoing Phase II studies for various Metabolic Syndrome Hybrid Disorders (MASH)
In this Review, we trace the recent evolution of obesity pharmacotherapy from GLP1 receptor agonists to next-generation multi-receptor agonists, alongside strategies that incorporate oral formulations, weight-loss quality approaches and tissue-specific drug targeting
The evaporation of the compounded drug supply could come as a shock to patients
In an analysis of patient records tracked by Epic Research, over 400,000 patients treated with GLP-1 agonists for one year at peak doses for diabetes or weight loss, liraglutide was the least effective (Bartelt K et al, Epic Research
Patients should weigh the risks and benefits before using compounded meds as part of their treatment
